JAMILA WHEELER-SMITH: Open Payments
NPI 1730645169 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,527 in 48 payments from 9 companies in 2025. Trend: 2023 $648 · 2024 $582 · 2025 $1,527
Food & beverage: $1,416Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $452 |
| E.R. Squibb & Sons, L.L.C. | 6 | $306 |
| ABBVIE INC. | 7 | $276 |
| Neurocrine BioSciences, Inc. | 11 | $212 |
| Alkermes, Inc. | 4 | $104 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $13 |
Products named: UZEDY, COBENFY, VRAYLAR, INGREZZA, ARISTADA, CAPLYTA, LYBALVI, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
